| Style | Citing Format |
|---|---|
| MLA | Lefort M, et al.. "Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis." BMC Medical Research Methodology, vol. 22, no. 1, 2022, pp. -. |
| APA | Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Seze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrunfrenay C, Moreau T, Berger E, Clavelou P, Pelletier J, ... Leray E (2022). Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis. BMC Medical Research Methodology, 22(1), -. |
| Chicago | Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey R, Debouverie M, Edan G, et al.. "Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis." BMC Medical Research Methodology 22, no. 1 (2022): -. |
| Harvard | Lefort M et al. (2022) 'Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis', BMC Medical Research Methodology, 22(1), pp. -. |
| Vancouver | Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey R, Debouverie M, et al.. Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis. BMC Medical Research Methodology. 2022;22(1):-. |
| BibTex | @article{ author = {Lefort M and Sharmin S and Andersen JB and Vukusic S and Casey R and Debouverie M and Edan G and Ciron J and Ruet A and De Seze J and Maillart E and Zephir H and Labauge P and Defer G and Lebrunfrenay C and Moreau T and Berger E and Clavelou P and Pelletier J and Stankoff B and Gout O and Thouvenot E and Heinzlef O and Alkhedr A and Bourre B and Casez O and Cabre P and Montcuquet A and Wahab A and Camdessanche JP and Maurousset A and Ben Nasr H and Hankiewicz K and Pottier C and Maubeuge N and Dimitriboulos D and Nifle C and Laplaud DA and Horakova D and Havrdova EK and Alroughani R and Izquierdo G and Eichau S and Ozakbas S and Patti F and Onofrj M and Lugaresi A and Terzi M and Grammond P and Grandmaison F and Yamout B and Prat A and Girard M and Duquette P and Boz C and Trojano M and Mccombe P and Slee M and Lechnerscott J and Turkoglu R and Sola P and Ferraro D and Granella F and Shaygannejad V and Prevost J and Maimone D and Skibina O and Buzzard K and Van Der Walt A and Karabudak R and Van Wijmeersch B and Csepany T and Spitaleri D and Vucic S and Kochhenriksen N and Sellebjerg F and Soerensen PS and Hilt Christensen CC and Rasmussen PV and Jensen MB and Frederiksen JL and Bramow S and Mathiesen HK and Schreiber KI and Butzkueven H and Magyari M and Kalincik T and Leray E}, title = {Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis}, journal = {BMC Medical Research Methodology}, volume = {22}, number = {1}, pages = {-}, year = {2022} } |
| RIS | TY - JOUR AU - Lefort M AU - Sharmin S AU - Andersen JB AU - Vukusic S AU - Casey R AU - Debouverie M AU - Edan G AU - Ciron J AU - Ruet A AU - De Seze J AU - Maillart E AU - Zephir H AU - Labauge P AU - Defer G AU - Lebrunfrenay C AU - Moreau T AU - Berger E AU - Clavelou P AU - Pelletier J AU - Stankoff B AU - Gout O AU - Thouvenot E AU - Heinzlef O AU - Alkhedr A AU - Bourre B AU - Casez O AU - Cabre P AU - Montcuquet A AU - Wahab A AU - Camdessanche JP AU - Maurousset A AU - Ben Nasr H AU - Hankiewicz K AU - Pottier C AU - Maubeuge N AU - Dimitriboulos D AU - Nifle C AU - Laplaud DA AU - Horakova D AU - Havrdova EK AU - Alroughani R AU - Izquierdo G AU - Eichau S AU - Ozakbas S AU - Patti F AU - Onofrj M AU - Lugaresi A AU - Terzi M AU - Grammond P AU - Grandmaison F AU - Yamout B AU - Prat A AU - Girard M AU - Duquette P AU - Boz C AU - Trojano M AU - Mccombe P AU - Slee M AU - Lechnerscott J AU - Turkoglu R AU - Sola P AU - Ferraro D AU - Granella F AU - Shaygannejad V AU - Prevost J AU - Maimone D AU - Skibina O AU - Buzzard K AU - Van Der Walt A AU - Karabudak R AU - Van Wijmeersch B AU - Csepany T AU - Spitaleri D AU - Vucic S AU - Kochhenriksen N AU - Sellebjerg F AU - Soerensen PS AU - Hilt Christensen CC AU - Rasmussen PV AU - Jensen MB AU - Frederiksen JL AU - Bramow S AU - Mathiesen HK AU - Schreiber KI AU - Butzkueven H AU - Magyari M AU - Kalincik T AU - Leray E TI - Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis JO - BMC Medical Research Methodology VL - 22 IS - 1 SP - EP - PY - 2022 ER - |